A new biotech launches with $180M to fund autoimmune drug trials

After spin-off, Anaptys shifts to royalty-only model with $140M-$145M cash

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

AnaptysBio completes spin-off of First Tracks Biotherapeutics

AnaptysBio rises after completing First Tracks spinoff

AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties